Hence, we hypothesized that the decreased level of HO-1 in patients with advanced-stage PD may be due to a mechanism by which the body defends against damage caused by HO-1 overexpression after the pathological features of PD have developed. The gene discussed is HMOX1; the disease is Parkinson disease.